Clinical trials: Squamous Cell Carcinoma of the Head and Neck
Head and Neck Squamous Cell Carcinoma
Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma
A multicenter, randomized, controlled, open-label, Phase II/III clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative…
- Trial name
- NimoBenSeq (NCT07535567)
- Testing
- Nimotuzumab, Nimotuzumab, Benmelstobart, Postoperative Radiotherapy
- Volunteers
- 386 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Squamous Cell Carcinoma
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- HNSCC (NCT06332092)
- Testing
- FID007
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Fulgent Pharma LLC.
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Head and Neck Squamous Cell Carcinoma
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
- Trial name
- NCT03602911
- Testing
- The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- West Virginia University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
This is a monocentric, non-randomized, prospective, in silico feasibility study conducted by Strasbourg Europe Cancerology Institute.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- OPPIDOM (NCT04801472)
- Testing
- Optimisation of dental implant sites protection from irradiation
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Head and Neck Neoplasms
Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival. Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical…
- Trial name
- Tax-Nazo (NCT00772681)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Head and Neck Squamous Cell Carcinoma
Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva
Prospective study for therapy monitoring of locally advanced and metastatic head and neck cancer patients by detection of circulating tumor nucleic acids in peripheral blood and saliva
- Trial name
- KOHACIN (NCT05122507)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Technical University of Munich
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002711
- Testing
- chemotherapy, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma HNSCC
Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)
The use of digital strategies to systematically monitor patients' symptoms in clinical settings allows problems to be detected at an early stage before they worsen or lead to complications.
- Trial name
- WEBNECK (NCT07190755)
- Testing
- Remote symptoms moniotring
- Where
- 2 sites in France
- Volunteers
- 192 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Squamous Cell Carcinoma
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients.
- Trial name
- HENEPET (NCT04196985)
- Testing
- PET/MRI, PET/CT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
Head and Neck Cancer, Carcinoma, Squamous
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
- Trial name
- NCT00591149
- Testing
- Oxaliplatin, Docetaxel, Cetuximab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Kansas Medical Center
Squamous Cell Carcinoma of Head and Neck
Non Elective Vulnerable Elderly Radiotherapy
To evaluate whether patients defined "non-fit for curative non-surgical radio-chemotherapy" and therefore treated with RT alone addressed only to non-elective sites of disease, could obtain a non-inferior loco-regional control…
- Trial name
- NEVER (NCT04832555)
- Testing
- Non elective radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero Universitaria Policlinico Modena
Esophageal Cancer
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than…
- Trial name
- NCT02461043
- Testing
- paclitaxel; cisplatin, radiation
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
This study will investigate the clinical validity and clinical utility of the OncoPrism-HNSCC (Head and Neck Squamous Cell Carcinoma) test.
- Trial name
- PREDAPT-HNSCC2 (NCT05296135)
- Testing
- OncoPrism-HNSCC™
- Where
- United States
- Sponsor
- Cofactor Genomics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.